📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Reply to Banda et al., "Interpretation of Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine". (2019)

First Author: Walimbwa S

Attributed to: Centre for Drug Safety Science (CDSS) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1128/aac.00593-19

PubMed Identifier: 31126921

Publication URI: http://europepmc.org/abstract/MED/31126921

Type: Journal Article/Review

Volume: 63

Parent Publication: Antimicrobial agents and chemotherapy

Issue: 6

ISSN: 0066-4804